Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:CUR
- CUSIP: N/A
- Web: www.neuralstem.com
Capitalization:- Market Cap: $67.03 million
- Outstanding Shares: 11,899,000
Average Prices:- 50 Day Moving Avg: $5.50
- 200 Day Moving Avg: $4.66
- 52 Week Range: $2.20 - $6.60
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $16,246.00
- Price / Sales: 2,058.12
- Book Value: $0.83 per share
- Price / Book: 3.39
Profitability:- EBIDTA: ($18,210,000.00)
- Net Margins: -191,652.16%
- Return on Equity: -425.79%
- Return on Assets: -122.42%
Debt:- Current Ratio: 3.41%
- Quick Ratio: 3.41%
Misc:- Average Volume: 103,859 shs.
- Beta: 2.08
- Short Ratio: 9.82
Frequently Asked Questions for Neuralstem (NASDAQ:CUR)
What is Neuralstem's stock symbol?
Neuralstem trades on the NASDAQ under the ticker symbol "CUR."
How were Neuralstem's earnings last quarter?
Neuralstem, Inc. (NASDAQ:CUR) posted its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. Neuralstem had a negative net margin of 191,652.16% and a negative return on equity of 425.79%. View Neuralstem's Earnings History.
Where is Neuralstem's stock going? Where will Neuralstem's stock price be in 2017?
3 analysts have issued 1-year target prices for Neuralstem's shares. Their forecasts range from $1.20 to $4.00. On average, they expect Neuralstem's stock price to reach $2.79 in the next year. View Analyst Ratings for Neuralstem.
Who are some of Neuralstem's key competitors?
Some companies that are related to Neuralstem include Adamis Pharmaceuticals Corporation (ADMP), Aralez Pharmaceuticals (ARLZ), Concordia International Corp. (CXRX), Intellipharmaceutics International (IPCI), Innocoll Holdings (INNL), Diurnal Group PLC (DNL), Juniper Pharmaceuticals (JNP), Amryt Pharma PLC (AMYT), SCYNEXIS (SCYX), Histogenics Corporation (HSGX), BioLife Solutions (BLFS), Marinus Pharmaceuticals (MRNS), Evoke Pharma (EVOK), Pernix Therapeutics Holdings (PTX), Eyegate Pharmaceuticals (EYEG), Immune Pharmaceuticals (IMNP), Venture Life Group PLC (VLG) and Galena Biopharma (GALE).
Who are Neuralstem's key executives?
Neuralstem's management team includes the folowing people:
- Richard J. Daly, Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer
- Scott V. Ogilvie, Independent Director
- William C. Oldaker, Independent Director
- Sandford D. Smith, Independent Director
- Stanley I. Westreich, Independent Director
How do I buy Neuralstem stock?
Shares of Neuralstem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuralstem's stock price today?
One share of Neuralstem stock can currently be purchased for approximately $2.81.
MarketBeat Community Rating for Neuralstem (NASDAQ CUR)MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Neuralstem (NASDAQ:CUR)Earnings History by Quarter for Neuralstem (NASDAQ CUR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2016 | Q3 | ($0.03) | ($0.05) | | | View | N/A |  |
| 8/11/2016 | Q2 | ($0.05) | ($0.04) | $2.50 million | $2.50 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.06) | ($0.07) | | | View | N/A | |
| 3/14/2016 | Q4 | ($0.07) | ($0.05) | | | View | N/A | |
| 11/9/2015 | Q315 | ($0.07) | ($0.06) | | | View | N/A | |
| 8/10/2015 | Q2 | ($0.06) | ($0.06) | | | View | N/A | |
| 5/8/2015 | Q115 | ($0.07) | ($0.06) | | $2.92 million | View | N/A | |
| 4/20/2015 | | ($0.07) | ($0.06) | | | View | N/A | |
| 3/16/2015 | Q4 2014 | ($0.05) | ($0.06) | | $0.01 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.05) | ($0.05) | | $0.01 million | View | N/A | |
| 8/8/2014 | Q214 | ($0.05) | ($0.08) | $0.10 million | $0.01 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.05) | ($0.04) | $0.35 million | $0.00 million | View | N/A | |
| 3/10/2014 | Q4 2013 | ($0.06) | ($0.04) | | | View | N/A | |
| 11/11/2013 | Q3 | ($0.04) | ($0.09) | | | View | N/A | |
| 8/9/2013 | Q213 | ($0.05) | ($0.09) | $0.08 million | $0.00 million | View | N/A | |
| 11/9/2012 | Q312 | ($0.04) | ($0.04) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Neuralstem (NASDAQ:CUR)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Neuralstem (NASDAQ:CUR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Neuralstem (NASDAQ:CUR)Insider Ownership Percentage: 15.43%
Institutional Ownership Percentage: 12.46%
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/17/2017 | Richard J Daly | CEO | Buy | 7,500 | $4.00 | $30,000.00 | |
| 3/24/2017 | Jones Jonathan Brian Lloyd | CFO | Buy | 5,455 | $5.50 | $30,002.50 | |
| 2/24/2017 | Richard J Daly | CEO | Buy | 2,591 | $3.86 | $10,001.26 | |
| 1/25/2017 | Richard J Daly | CEO | Buy | 2,841 | $3.52 | $10,000.32 | |
| 12/23/2016 | Richard J Daly | CEO | Buy | 32,259 | $0.31 | $10,000.29 | |
| 11/25/2016 | Richard J Daly | CEO | Buy | 35,715 | $0.28 | $10,000.20 | |
| 10/25/2016 | Richard J Daly | CEO | Buy | 35,715 | $0.28 | $10,000.20 | |
| 9/23/2016 | Richard J Daly | CEO | Buy | 31,250 | $0.32 | $10,000.00 | |
| 11/16/2015 | Karl Johe | Insider | Sell | 25,000 | $1.09 | $27,250.00 | |
| 11/9/2015 | Karl Johe | Insider | Sell | 25,000 | $1.18 | $29,500.00 | |
| 11/2/2015 | Karl Johe | Insider | Sell | 25,000 | $1.17 | $29,250.00 | |
| 10/26/2015 | Karl Johe | Insider | Sell | 25,000 | $1.13 | $28,250.00 | |
| 10/19/2015 | Karl Johe | Insider | Sell | 25,000 | $1.23 | $30,750.00 | |
| 10/12/2015 | Karl Johe | Insider | Sell | 25,000 | $1.31 | $32,750.00 | |
| 10/5/2015 | Karl Johe | Insider | Sell | 25,000 | $1.26 | $31,500.00 | |
| 9/28/2015 | Karl Johe | Insider | Sell | 25,000 | $1.64 | $41,000.00 | |
| 9/21/2015 | Karl Johe | Insider | Sell | 25,000 | $1.52 | $38,000.00 | |
| 9/2/2014 | Karl Johe | Insider | Sell | 6,000 | $4.09 | $24,540.00 | |
| 8/1/2014 | Karl Johe | Insider | Sell | 6,000 | $2.78 | $16,680.00 | |
| 7/1/2014 | Karl Johe | Insider | Sell | 6,000 | $4.17 | $25,020.00 | |
| 6/2/2014 | Karl Johe | Insider | Sell | 6,000 | $4.25 | $25,500.00 | |
| 5/5/2014 | William Clyde Oldaker | Director | Buy | 15,235 | $3.50 | $53,322.50 | |
| 4/22/2014 | Richard Garr | CEO | Sell | 7,000 | $4.25 | $29,750.00 | |
| 4/1/2014 | Karl Johe | Insider | Sell | 6,000 | $4.11 | $24,660.00 | |
| 3/20/2014 | Karl Johe | Insider | Sell | 6,000 | $4.04 | $24,240.00 | |
| 10/18/2013 | Karl Johe | Insider | Sell | 10,000 | $2.44 | $24,400.00 | |
| 9/20/2013 | Karl Johe | Insider | Sell | 10,000 | $2.62 | $26,200.00 | |
| 9/19/2013 | Karl Johe | Insider | Sell | 10,000 | $2.61 | $26,100.00 | |
| 8/20/2013 | Karl Johe | Insider | Sell | 20,000 | $1.55 | $31,000.00 | |
| 7/22/2013 | Karl Johe | Insider | Sell | 12,800 | $1.62 | $20,736.00 | |
| 6/20/2013 | Karl Johe | Insider | Sell | 12,800 | $1.40 | $17,920.00 | |
| 6/7/2013 | Richard Garr | CEO | Sell | 6,000 | $1.42 | $8,520.00 | |
| 5/20/2013 | Karl Johe | Insider | Sell | 12,800 | $1.51 | $19,328.00 | |
| 2/25/2013 | Richard Garr | CEO | Sell | 12,000 | $1.15 | $13,800.00 | |
| 11/20/2012 | Karl Johe | Insider | Sell | 12,800 | $1.00 | $12,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Neuralstem (NASDAQ:CUR)
Latest Headlines for Neuralstem (NASDAQ:CUR)
| Source: |
|
| Date | Headline |
|---|
 | Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX
www.rttnews.com - July 26 at 3:43 AM |
 | Mid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss - Benzinga
www.benzinga.com - July 25 at 10:39 PM |
 | UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss - MarketWatch
www.marketwatch.com - July 25 at 10:39 PM |
 | Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder
finance.yahoo.com - July 25 at 5:37 PM |
| UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss
finance.yahoo.com - July 25 at 5:37 PM |
| ETFs with exposure to Neuralstem, Inc. : July 4, 2017
finance.yahoo.com - July 5 at 12:22 AM |
| Neuralstem Added to the Russell Microcap® Index
finance.yahoo.com - June 26 at 5:23 PM |
 | Neuralstem, Inc. (CUR) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 9 at 3:58 PM |
| Neuralstem, Inc. (CUR) Sees Large Decline in Short Interest
www.americanbankingnews.com - June 3 at 2:20 PM |
| ETFs with exposure to Neuralstem, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 6:04 PM |
| ETFs with exposure to Neuralstem, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 4:22 PM |
| Richard J. Daly Buys 7,500 Shares of Neuralstem, Inc. (CUR) Stock
www.americanbankingnews.com - May 18 at 1:32 PM |
 | Neuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder
www.streetinsider.com - May 17 at 9:42 PM |
| Neuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder - StreetInsider.com
www.streetinsider.com - May 17 at 4:41 PM |
| Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
finance.yahoo.com - May 17 at 4:41 PM |
| Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:08 PM |
| Today's Research Reports on Stocks to Watch: MannKind and Neuralstem
finance.yahoo.com - May 11 at 5:14 PM |
| ETFs with exposure to Neuralstem, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:14 PM |
 | Gainers & Losers Of May 10: CUR, TEAR, PRTO, CXRX, DERM...
www.finanznachrichten.de - May 11 at 2:49 AM |
| Zacks: Neuralstem, Inc. (CUR) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 10 at 8:44 PM |
 | Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
globenewswire.com - May 10 at 4:47 PM |
| Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
finance.yahoo.com - May 10 at 4:47 PM |
 | Neuralstem, Inc. (CUR)
seekingalpha.com - May 4 at 9:45 PM |
| Neuralstem (CUR) Receiving Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 21 at 6:28 PM |
 | BioAxone BioSciences Appoints Dr. Catherine Sohn to Lead Corporate Development
www.businesswire.com - April 20 at 4:45 PM |
| ETFs with exposure to Neuralstem, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 4:34 PM |
| Neuralstem (CUR) Getting Somewhat Negative Media Coverage, Report Finds
www.americanbankingnews.com - April 13 at 12:54 PM |
| Neuralstem (CUR) Adds Four Cohorts to Ongoing Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury - StreetInsider.com
www.streetinsider.com - April 13 at 11:48 AM |
| Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury
finance.yahoo.com - April 12 at 11:22 AM |
| ETFs with exposure to Neuralstem, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:16 AM |
| Jones Jonathan Brian Lloyd Acquires 5,455 Shares of Neuralstem, Inc. (CUR) Stock
www.americanbankingnews.com - March 27 at 11:05 PM |
| NEURALSTEM, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 23 at 5:09 PM |
 | Neuralstem Reports Year End 2016 Fiscal Results and Business Update
us.rd.yahoo.com - March 23 at 5:09 PM |
| Neuralstem (CUR) Reports Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury - StreetInsider.com
www.streetinsider.com - March 11 at 10:09 AM |
| Neuralstem, Inc. (CUR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 11 at 12:43 AM |
| Today's Research Reports on Market Movers: Neuralstem and Real Goods Solar
us.rd.yahoo.com - March 10 at 5:39 PM |
| Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury
us.rd.yahoo.com - March 9 at 5:11 PM |
| Neuralstem to Present at 29th Annual ROTH Conference - GlobeNewswire (press release)
www.globenewswire.com - March 8 at 10:20 PM |
| Neuralstem (CUR) Announces Publication of NSI-189 Preclinical Data
www.streetinsider.com - March 1 at 1:18 PM |
| Neuralstem (CUR) Announces Publication of NSI-189 Preclinical Data - StreetInsider.com
www.streetinsider.com - February 28 at 4:48 PM |
| Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology
us.rd.yahoo.com - February 28 at 10:33 AM |
| NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 27 at 5:47 PM |
| Neuralstem Announces Issuance of U.S. Patent Covering NSI-189
us.rd.yahoo.com - February 22 at 4:49 PM |
| 7:04 am Neuralstem confirms that U.S. Patent No. 9572807 was issued by the United States Patent and Trademark Office for NSI-189 the lead compound in Neuralstem's neurogenic small molecule program in development for the treatment of major d
us.rd.yahoo.com - February 22 at 4:49 PM |
| Neuralstem (CUR) Confirms US Patent Covering NSI-189 - StreetInsider.com
www.streetinsider.com - February 22 at 9:25 AM |
| UPDATE: Neuralstem (CUR) Halted on LUDP After Announcing Phase 2 NSI-189 Data Now Expected Ahead of Schedule
www.streetinsider.com - February 16 at 6:39 PM |
| UPDATE: Neuralstem (CUR) Halted on LUDP After Announcing Phase 2 NSI-189 Data Now Expected Ahead of Schedule
www.streetinsider.com - February 16 at 6:39 PM |
| NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 16 at 6:39 PM |
| 18 Biggest Mid-Day Gainers For Thursday
feeds.benzinga.com - February 16 at 1:42 PM |
| 18 Biggest Mid-Day Gainers For Thursday - Benzinga
www.benzinga.com - February 16 at 1:38 PM |
Neuralstem (CUR) Chart for Wednesday, July, 26, 2017
